Our investments have contributed to the development of numerous marketed products. We take pride in having contributed to their success.


Extended release, oral ion-channel blocker to improve walking in Multiple Sclerosis patients.

Opioid agonist for the management of severe pain.

Topical testosterone for treating males with low or no testosterone.

Indicated for use with other heart medicines to treat heart failure in African American patients.

First bi-specific antibody for the treatment of acute lymphoblastic leukemia.

Generic LOVENOX®, low molecular-weight heparin to prevent and treat deep vein thrombosis.

Injectable bradykinin receptor antagonist for the treatment of acute hereditary angioedema.

The first oncolytic viral therapy for the local treatment of recurrent melanoma.

Subcutaneously administered GLP-1 agonist for type 2 diabetes.

Immediate-release, oral oxycodone HCl for acute and chronic pain.

An oral opioid receptor ligand for treating alcohol dependence.

Novel nasal spray formulation of an NSAID for pain management.

Inhalable bronchodilator treatment for chronic obstructive pulmonary disease.

Extended-release tablets for treating chronic hepatitis C virus infection.

Used with levodopa to control motor fluctuations in Parkinson’s disease patients.

Indicated for treating chorea associated with Huntington’s disease.

Instruments and Research Tools

Andrew, the liquid handling robot designed to enhance the reproducibility and efficiency of the pipetting process.

High-throughput system for PCR-based genotyping, gene expression, and microRNA analysis.

Sophion Qube, a high throughput system for ion channel screening.

Medical Devices

CryoConsole: Cardiac Cryoablation System for treating paroxysmal atrial fibrillation.

Hydrosurgery system for minimally invasive spine surgery.

Diagnostics and Other Products

Weed control solution containing genetically modified soybean plants and tailor made herbicides.

The first blood test for colorectal cancer screening.

Assay for detection of mSHOX2 in patients suspected of having lung cancer.

Breast cancer recurrence assay.

Omega Fund Management, LLC and its affiliates (collectively, “Omega”) only owns its own trademarks, with all other trademarks being the property of their respective owners. Nothing on this website should be construed as granting, by implication, estoppel, or otherwise, any license or right to use any trademark displayed on this website without the prior written consent of the trademark owner. Nothing on this website should be construed as promoting or recommending any of the drugs/products that are displayed on this website.